Rapid Micro Biosystems to Participate in Healthcare Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RPID?
Source: Newsfilter
- Forum Participation: Rapid Micro Biosystems is scheduled to participate in a virtual Q&A session at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, which is expected to attract investor interest and enhance the company's visibility in the healthcare sector.
- Technological Innovation: The flagship Growth Direct system automates microbial quality control testing workflows, significantly improving operational efficiency and data compliance in the pharmaceutical industry, enabling customers to make faster decisions to ensure the safe and consistent supply of healthcare products.
- Global Business Presence: Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems has a manufacturing base in Lowell and global locations in Switzerland, Germany, and the Netherlands, showcasing its extensive influence in international markets.
- Investor Relations Enhancement: The company will provide a live webcast and replay of the forum on its investor relations website, further strengthening engagement with investors, enhancing transparency and trust, and supporting the company's future performance in the capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RPID?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RPID
Wall Street analysts forecast RPID stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.130
Low
8.00
Averages
8.00
High
8.00
Current: 4.130
Low
8.00
Averages
8.00
High
8.00
About RPID
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Micro Biosystems to Participate in Healthcare Forum
- Forum Participation: Rapid Micro Biosystems is scheduled to participate in a virtual Q&A session at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, which is expected to attract investor interest and enhance the company's visibility in the healthcare sector.
- Technological Innovation: The flagship Growth Direct system automates microbial quality control testing workflows, significantly improving operational efficiency and data compliance in the pharmaceutical industry, enabling customers to make faster decisions to ensure the safe and consistent supply of healthcare products.
- Global Business Presence: Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems has a manufacturing base in Lowell and global locations in Switzerland, Germany, and the Netherlands, showcasing its extensive influence in international markets.
- Investor Relations Enhancement: The company will provide a live webcast and replay of the forum on its investor relations website, further strengthening engagement with investors, enhancing transparency and trust, and supporting the company's future performance in the capital markets.
See More
Rapid Micro Biosystems Grants Stock Awards to New Employees
- Stock Award Program: On February 2, 2026, Rapid Micro Biosystems granted 205,000 restricted stock units (RSUs) and 168,000 stock options to three new employees as a material inducement for employment, highlighting the company's commitment to attracting talent.
- Option Exercise Price: The stock options have an exercise price of $4.19 per share, matching the closing price of the common stock on the grant date, ensuring that employees can achieve reasonable financial returns when the company performs well.
- Grant Plan Details: Under the amended Inducement Plan, 25% of the stock options will vest on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring ongoing contributions from employees during their tenure.
- Company Background: Rapid Micro Biosystems focuses on providing critical automation solutions to enhance the efficiency and safety of biopharmaceutical product manufacturing, with its flagship Growth Direct system aimed at modernizing traditional microbial quality control testing processes to improve overall operational efficiency in the pharmaceutical industry.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M
- Quarterly Revenue Growth: Rapid Micro Biosystems reported approximately $11.3 million in revenue for Q4, indicating sustained growth and strong market demand in the biosystems sector.
- Recurring Revenue Increase: The expected recurring revenue for Q4 2025 is approximately $4.6 million, representing a 10% growth compared to the prior-year period, reflecting steady improvements in customer base and product demand.
- Guidance Upgrade: Rapid Micro Biosystems raised its 2025 revenue guidance to at least $33 million, demonstrating the company's confidence in future performance and ongoing market demand.
- Surge in Multi-System Orders: The company secured a record number of multi-system orders during the reporting period, driving revenue growth and accelerating margin improvement, showcasing its competitiveness and enhanced market position.
See More
Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%
- Quarterly Revenue Expectation: Rapid Micro Biosystems anticipates preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, reflecting a robust 37% year-over-year growth that underscores the company's strong performance in the life sciences technology sector.
- Full-Year Revenue Outlook: The company projects full-year 2025 revenue to be around $33.6 million, representing a year-on-year growth of about 20%, indicating sustained demand for its products and increasing market recognition.
- Recurring Revenue Growth: Expected recurring revenue for the fourth quarter is $4.6 million, while full-year recurring revenue is forecasted at $17.8 million, showcasing the company's solid performance in establishing stable revenue streams.
- Future Guidance: Rapid Micro Biosystems plans to release full audited results and its 2026 outlook in the first quarter, further enhancing investor confidence in the company's future growth trajectory.
See More
Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved
Third Quarter Financial Performance: Rapid Micro Biosystems Inc reported Q3 revenue of $7.8 million, with consumables revenue up 40% and service revenue increasing by 12%, contributing to a 30% year-over-year rise in recurring revenue.
Record Multi-System Order: The company secured a significant multi-system order from a top biopharma customer, indicating strong commercial momentum, although they anticipate a temporary decrease in service revenue in Q4.
Collaboration and Margin Outlook: Progress with Millipore Sigma is expected to enhance margins starting in the second half of 2026, despite current product margins being slightly negative.
Future Expectations: The company expects onshoring to positively impact business in 2027 and beyond, while gross margins for Q4 are projected to be in the mid-single digits due to ongoing profitability challenges.
See More
Rapid Micro Biosystems to Participate in Healthcare Forum
- Forum Participation: Rapid Micro Biosystems is scheduled to participate in a virtual Q&A session at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, which is expected to attract investor interest and enhance the company's visibility in the healthcare sector.
- Technological Innovation: The flagship Growth Direct system automates microbial quality control testing workflows, significantly improving operational efficiency and data compliance in the pharmaceutical industry, enabling customers to make faster decisions to ensure the safe and consistent supply of healthcare products.
- Global Business Presence: Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems has a manufacturing base in Lowell and global locations in Switzerland, Germany, and the Netherlands, showcasing its extensive influence in international markets.
- Investor Relations Enhancement: The company will provide a live webcast and replay of the forum on its investor relations website, further strengthening engagement with investors, enhancing transparency and trust, and supporting the company's future performance in the capital markets.
See More
Rapid Micro Biosystems Grants Stock Awards to New Employees
- Stock Award Program: On February 2, 2026, Rapid Micro Biosystems granted 205,000 restricted stock units (RSUs) and 168,000 stock options to three new employees as a material inducement for employment, highlighting the company's commitment to attracting talent.
- Option Exercise Price: The stock options have an exercise price of $4.19 per share, matching the closing price of the common stock on the grant date, ensuring that employees can achieve reasonable financial returns when the company performs well.
- Grant Plan Details: Under the amended Inducement Plan, 25% of the stock options will vest on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring ongoing contributions from employees during their tenure.
- Company Background: Rapid Micro Biosystems focuses on providing critical automation solutions to enhance the efficiency and safety of biopharmaceutical product manufacturing, with its flagship Growth Direct system aimed at modernizing traditional microbial quality control testing processes to improve overall operational efficiency in the pharmaceutical industry.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M
- Quarterly Revenue Growth: Rapid Micro Biosystems reported approximately $11.3 million in revenue for Q4, indicating sustained growth and strong market demand in the biosystems sector.
- Recurring Revenue Increase: The expected recurring revenue for Q4 2025 is approximately $4.6 million, representing a 10% growth compared to the prior-year period, reflecting steady improvements in customer base and product demand.
- Guidance Upgrade: Rapid Micro Biosystems raised its 2025 revenue guidance to at least $33 million, demonstrating the company's confidence in future performance and ongoing market demand.
- Surge in Multi-System Orders: The company secured a record number of multi-system orders during the reporting period, driving revenue growth and accelerating margin improvement, showcasing its competitiveness and enhanced market position.
See More
Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%
- Quarterly Revenue Expectation: Rapid Micro Biosystems anticipates preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, reflecting a robust 37% year-over-year growth that underscores the company's strong performance in the life sciences technology sector.
- Full-Year Revenue Outlook: The company projects full-year 2025 revenue to be around $33.6 million, representing a year-on-year growth of about 20%, indicating sustained demand for its products and increasing market recognition.
- Recurring Revenue Growth: Expected recurring revenue for the fourth quarter is $4.6 million, while full-year recurring revenue is forecasted at $17.8 million, showcasing the company's solid performance in establishing stable revenue streams.
- Future Guidance: Rapid Micro Biosystems plans to release full audited results and its 2026 outlook in the first quarter, further enhancing investor confidence in the company's future growth trajectory.
See More
Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved
Third Quarter Financial Performance: Rapid Micro Biosystems Inc reported Q3 revenue of $7.8 million, with consumables revenue up 40% and service revenue increasing by 12%, contributing to a 30% year-over-year rise in recurring revenue.
Record Multi-System Order: The company secured a significant multi-system order from a top biopharma customer, indicating strong commercial momentum, although they anticipate a temporary decrease in service revenue in Q4.
Collaboration and Margin Outlook: Progress with Millipore Sigma is expected to enhance margins starting in the second half of 2026, despite current product margins being slightly negative.
Future Expectations: The company expects onshoring to positively impact business in 2027 and beyond, while gross margins for Q4 are projected to be in the mid-single digits due to ongoing profitability challenges.
See More
